Belumosudil (Rezurock®): A Comprehensive Monograph on the First-in-Class Selective ROCK2 Inhibitor for Chronic Graft-Versus-Host Disease

1.0 Executive Summary

Belumosudil, marketed under the brand name Rezurock®, is a first-in-class, orally administered small molecule that functions as a selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). Its approval by the U.S. Food and Drug Administration (FDA) marks a significant advancement in the therapeutic landscape for chronic graft-versus-host disease (cGVHD), a severe, multi-system complication following allogeneic hematopoietic cell transplantation. Belumosudil is specifically indicated for the treatment of adult and pediatric patients aged 12 years and older with cGVHD who have experienced treatment failure after at least two prior lines of systemic therapy.[1] This indication addresses a critical unmet medical need in a patient population with limited effective options and substantial morbidity.

The therapeutic efficacy of Belumosudil is rooted in its novel mechanism of action, which uniquely targets the dual pathology of cGVHD: dysregulated inflammation and progressive fibrosis.[4] By selectively inhibiting ROCK2, Belumosudil orchestrates a sophisticated immunomodulatory effect, rebalancing the critical ratio of pro-inflammatory T helper 17 (Th17) cells to anti-inflammatory regulatory T (Treg) cells. This is achieved through the differential modulation of the STAT3 and STAT5 signaling pathways.[5] Concurrently, Belumosudil exerts a direct anti-fibrotic effect by inhibiting downstream pathways that lead to collagen deposition and tissue scarring.[5]

Clinical validation of this mechanism was established in the pivotal ROCKstar (KD025-213) trial, which demonstrated high and durable overall response rates (ORR) of approximately 75% in a heavily pre-treated and refractory cGVHD population.[8] Beyond objective responses, treatment with Belumosudil led to clinically meaningful improvements in patient-reported symptoms, a significant corticosteroid-sparing effect, and a high 2-year overall survival rate, underscoring its profound clinical benefit.[9]

The safety profile of Belumosudil is generally considered manageable. The most frequently reported adverse reactions include infections, asthenia, nausea, diarrhea, and hypertension.[8] Key warnings and precautions include the risk of embryo-fetal toxicity, necessitating stringent contraceptive measures for both male and female patients, and the potential for hepatotoxicity, which requires regular monitoring of liver function tests.[11] The drug's pharmacokinetic profile is characterized by a significant food effect and metabolism primarily via CYP3A4, making it susceptible to important drug-drug interactions that require careful management and dose adjustments.[14]

In summary, Belumosudil represents a paradigm shift in the management of advanced cGVHD. It moves beyond the limitations of broad immunosuppression to a targeted, pathway-centric approach that recalibrates the underlying pathophysiology of the disease. Its proven efficacy and manageable safety profile have established it as a vital therapeutic option for patients with refractory cGVHD.

2.0 Drug Profile and Chemical Characteristics

This section provides the foundational identification and chemical properties of Belumosudil, establishing its identity as a distinct therapeutic entity.

2.1 Systematic Identification

Belumosudil is a synthetic small molecule compound with a well-defined chemical structure and multiple identifiers used across research, clinical, and regulatory domains.

• Generic Name: Belumosudil.[1]
• Brand Name: The approved proprietary name for Belumosudil is Rezurock®.[1]
• Developmental Codes: During its preclinical and clinical development, Belumosudil was referred to by the codes KD-025 and SLx-2119.[16]
• Drug Type: Belumosudil is classified as a Small Molecule drug [User Query].

2.2 Chemical and Physical Properties

The precise chemical and physical characteristics of Belumosudil are essential for its manufacturing, formulation, and pharmacological activity.

• CAS Number: The Chemical Abstracts Service registry number for Belumosudil is 911417-87-3.[17]
• DrugBank ID: It is cataloged in the DrugBank database under the accession number DB16703.[18]
• Molecular Formula: The empirical formula for the Belumosudil base is C26​H24​N6​O2​.[18]
• Molecular Weight: The molecular weight of the base molecule is 452.51 g/mol.[16]
• IUPAC Name: The systematic chemical name according to the International Union of Pure and Applied Chemistry (IUPAC) nomenclature is 2-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide.[18]
• Formulation: Belumosudil is formulated for oral administration as a 200 mg, pale-yellow, film-coated oblong tablet.[14] Each tablet contains 200 mg of the active Belumosudil moiety, which is equivalent to 242.5 mg of Belumosudil mesylate.[20]

The formulation of Belumosudil as a mesylate salt is a critical aspect of its pharmaceutical design. The selection of a salt form is a deliberate and common strategy in drug development to optimize the physicochemical properties of an active pharmaceutical ingredient. Parent drug molecules, particularly complex organic structures like Belumosudil, may exhibit suboptimal characteristics such as poor aqueous solubility or chemical instability. These limitations can severely hinder the development of an effective oral dosage form, leading to low and erratic absorption and, consequently, unreliable therapeutic effects. By converting the Belumosudil base into its mesylate salt, the developers likely achieved a significant improvement in its aqueous solubility and dissolution rate. This enhancement is fundamental for an orally administered drug, as it promotes more consistent and predictable absorption from the gastrointestinal tract. This pharmaceutical optimization is therefore a foundational element that enables the reliable delivery of Belumosudil and contributes directly to its clinical viability as a chronic, self-administered therapy.

3.0 Mechanism of Action: Targeting the Nexus of Inflammation and Fibrosis

The therapeutic efficacy of Belumosudil in cGVHD is underpinned by its novel and highly specific mechanism of action. It functions as a potent, selective inhibitor of ROCK2, a key signaling protein that sits at the crossroads of the inflammatory and fibrotic pathways driving the pathophysiology of the disease.

3.1 Overview of the ROCK2 Pathway in cGVHD Pathophysiology

Chronic graft-versus-host disease is a complex, multi-system disorder arising after allogeneic hematopoietic cell transplantation. Its pathogenesis is characterized by a persistent and destructive cycle of immune dysregulation, leading to chronic inflammation, and an aberrant tissue repair response, resulting in progressive fibrosis.[1] These two processes are deeply intertwined and contribute to organ damage and significant patient morbidity.

The Rho-associated coiled-coil kinase (ROCK) signaling pathway has been identified as a central regulator of these pathological processes.[10] The ROCK family consists of two highly homologous serine/threonine kinase isoforms, ROCK1 and ROCK2. While both are involved in regulating cellular functions like cytoskeletal dynamics, cell motility, and apoptosis, emerging evidence has implicated the ROCK2 isoform as a critical driver of the specific immune and fibrotic responses that characterize cGVHD.[6] Overactivation of the ROCK2 signaling pathway is a key pathogenic feature in cGVHD, promoting the differentiation of pro-inflammatory T-cell subsets and stimulating the cellular machinery responsible for fibrosis.[1]

3.2 Selective Inhibition of ROCK2

Belumosudil is the first approved therapeutic agent designed to selectively inhibit the kinase activity of ROCK2.[1] Its inhibitory action is both potent and highly specific. Biochemical assays have demonstrated that Belumosudil inhibits ROCK2 with a half-maximal inhibitory concentration (

IC50​) of 0.105 µM. Crucially, it exhibits approximately 100-fold greater selectivity for ROCK2 over the ROCK1 isoform, for which the IC50​ is 24 µM.[11] This high degree of selectivity is a defining feature of the drug. While ROCK1 and ROCK2 share structural similarities, they have distinct physiological roles, and the broader inhibition of both isoforms by earlier, less selective compounds was often associated with dose-limiting toxicities that narrowed the therapeutic window.[21] By precisely targeting the ROCK2 isoform, which is more directly implicated in the specific pathology of cGVHD, Belumosudil can achieve its therapeutic effect while minimizing off-target effects related to ROCK1 inhibition. This molecular precision is fundamental to its favorable benefit-risk profile.

The molecular mechanism of inhibition involves Belumosudil binding competitively within the ATP-binding pocket of the ROCK2 enzyme. This occupation prevents the binding of ATP, the enzyme's natural substrate, thereby blocking the phosphorylation of downstream target proteins and effectively shutting down the signaling cascade.[6]

3.3 Dual Therapeutic Effect: Immunomodulation and Anti-Fibrosis

The inhibition of ROCK2 by Belumosudil produces a coordinated, dual therapeutic effect that simultaneously addresses both the inflammatory and fibrotic components of cGVHD. This distinguishes it from conventional immunosuppressants, positioning it as a true disease-modifying agent. It acts not as a simple inhibitor of a single target but as a modulator of an entire pathological pathway. By intervening at the upstream ROCK2 signaling hub, it orchestrates a downstream recalibration of the interconnected cellular programs that drive the disease.

3.3.1 Immunomodulation via STAT Signaling

A central feature of immune dysregulation in cGVHD is an imbalance between pro-inflammatory T helper 17 (Th17) cells and immunosuppressive regulatory T (Treg) cells.[6] Belumosudil acts to restore a healthy homeostatic balance through its influence on the Signal Transducer and Activator of Transcription (STAT) family of proteins.

• Downregulation of Pro-inflammatory Pathways: In pathogenic states, ROCK2 interacts with and phosphorylates STAT3, promoting the formation of signaling complexes that drive the differentiation and expansion of pro-inflammatory Th17 and T follicular helper (Tfh) cells.[5] These cells, in turn, produce key pathogenic cytokines such as Interleukin-17 (IL-17), Interleukin-21 (IL-21), and Interferon-gamma (IFN-γ), which perpetuate tissue inflammation.[1] By inhibiting ROCK2, Belumosudil prevents the phosphorylation of STAT3. This suppression of STAT3 signaling leads to a significant downregulation of the Th17 and Tfh cell populations and a corresponding reduction in the production of their associated pro-inflammatory cytokines.[5]
• Upregulation of Regulatory Pathways: In parallel, Belumosudil has the opposite effect on STAT5. Inhibition of ROCK2 leads to an increase in the phosphorylation of STAT5.[5] Activated STAT5 is a key transcription factor that promotes the development, survival, and function of Treg cells. These cells are crucial for maintaining immune tolerance and actively suppressing aberrant immune responses.[5]

Through this reciprocal modulation—downregulating STAT3 while upregulating STAT5—Belumosudil effectively recalibrates the immune system. It shifts the balance away from a pro-inflammatory Th17-dominant state and towards a more tolerant, Treg-dominant state, thereby quelling the autoimmune-like attack that characterizes cGVHD.

3.3.2 Anti-Fibrotic Action

Fibrosis, the pathological scarring of tissues, is a major cause of irreversible organ damage and mortality in cGVHD.[6] This process is driven by the excessive deposition of extracellular matrix components, such as collagen, by activated myofibroblasts.

• Inhibition of Myofibroblast Activation: The ROCK2 pathway is a critical activator of the fibrotic process. Pro-fibrotic mediators activate ROCK2, which then triggers a key change in the cell's cytoskeleton: the polymerization of globular actin (G-actin) into filamentous actin (F-actin) stress fibers.[5] This cytoskeletal rearrangement has a crucial downstream consequence. It liberates the Myocardin-Related Transcription Factor (MRTF) from its sequestration with G-actin in the cytoplasm, allowing it to translocate into the nucleus. Once in the nucleus, MRTF partners with other factors to drive the transcription of a suite of pro-fibrotic genes, including those for collagen and other extracellular matrix proteins.[5]
• Downregulation of Pro-Fibrotic Gene Expression: By inhibiting ROCK2, Belumosudil directly intervenes in this cascade. It prevents the polymerization of G-actin to F-actin, thereby keeping MRTF sequestered in the cytoplasm and unable to activate its target genes.[5] This effectively shuts down the cellular program for fibrosis. This anti-fibrotic mechanism has been demonstrated in preclinical animal models of cGVHD, where Belumosudil treatment led to decreased collagen deposition and delayed progression of scleroderma-like skin changes.[5] Further evidence comes from a clinical companion study to the ROCKstar trial, which showed a measurable reduction in collagen content in oral mucosal biopsies from patients who responded to Belumosudil therapy.[7]

This multi-pronged mechanism, which concurrently addresses both inflammation and fibrosis, makes Belumosudil uniquely suited to treat a complex, multi-faceted disease like cGVHD.

4.0 Clinical Pharmacology and Pharmacokinetics (ADME)

The clinical pharmacology of Belumosudil describes its absorption, distribution, metabolism, and excretion (ADME) profile. These pharmacokinetic parameters are essential for determining the appropriate dosing regimen, understanding potential variabilities in drug exposure, and identifying risks for drug-drug interactions.

4.1 Absorption

• Bioavailability: Following oral administration, Belumosudil is well-absorbed. In healthy subjects, the mean absolute oral bioavailability was determined to be 64%.[22]
• Time to Peak Concentration (Tmax​): At steady-state in patients with cGVHD, the median time to reach maximum plasma concentration (Tmax​) is approximately 1.3 to 2.5 hours after dosing, indicating relatively rapid absorption.[22]
• Food Effect: The absorption of Belumosudil is significantly influenced by the presence of food. Administration of a single 200 mg dose with a high-fat, high-calorie meal (800-1,000 calories, ~50% from fat) resulted in a substantial increase in drug exposure compared to administration in a fasted state. The maximum concentration (Cmax​) increased by 2.2-fold, and the total exposure (Area Under the Curve, AUC) increased by 2.0-fold.[14] This pronounced food effect is not a minor fluctuation; it represents a doubling of drug exposure that is clinically critical. Inconsistent administration with respect to meals could lead to highly variable plasma concentrations, resulting in either sub-therapeutic levels and potential treatment failure or supra-therapeutic peaks and increased risk of toxicity. This pharmacokinetic characteristic is the direct basis for the stringent clinical recommendation that Belumosudil must be taken with a meal at approximately the same time each day to ensure consistent and predictable absorption.[12]

4.2 Distribution

• Volume of Distribution: Belumosudil has a geometric mean volume of distribution of 184 L, which is significantly larger than the volume of plasma, indicating that the drug distributes extensively from the bloodstream into tissues throughout the body.[22]
• Protein Binding: In human plasma, Belumosudil is highly bound to proteins. In vitro studies show that it is 99.9% bound to human serum albumin and 98.6% bound to α1-acid glycoprotein.[16] This extensive binding means that only a very small fraction of the drug in circulation is unbound and pharmacologically active.

4.3 Metabolism

• Primary Metabolic Pathway: Belumosudil is predominantly cleared from the body via hepatic metabolism. The primary enzyme responsible for its metabolism is cytochrome P450 3A4 (CYP3A4).[13] This heavy reliance on a single major metabolic pathway makes Belumosudil highly susceptible to clinically significant drug-drug interactions. Co-administration with drugs that strongly induce or inhibit CYP3A4 activity can dramatically alter Belumosudil's clearance, leading to significant changes in its plasma concentration.
• Minor Metabolic Pathways: In vitro studies have shown that other enzymes, including CYP2C8, CYP2D6, and UDP-glucuronosyltransferase 1A9 (UGT1A9), contribute to the metabolism of Belumosudil to a lesser extent.[13]

4.4 Excretion

• Elimination Half-Life: The mean elimination half-life (t1/2​) of Belumosudil in patients is approximately 19 hours.[16] This relatively long half-life supports the convenience of a once-daily dosing regimen.
• Clearance: The systemic clearance of Belumosudil is 9.83 L/hour in patients.[22]
• Route of Elimination: The primary route of elimination for Belumosudil and its metabolites is through the feces, suggesting significant hepatic and/or biliary excretion. Following a single oral dose of radiolabeled Belumosudil in healthy subjects, 85% of the administered radioactivity was recovered in the feces. Of this amount, 30% was in the form of the unchanged parent drug. In contrast, less than 5% of the radioactive dose was recovered in the urine.[22]

Collectively, the ADME profile of Belumosudil necessitates a high degree of clinical vigilance. The combination of a significant food effect, primary metabolism by the highly inducible and inhibitable CYP3A4 enzyme, and high protein binding creates a scenario where therapeutic outcomes are directly linked to extrinsic factors. Adherence to administration instructions (i.e., taking with food) and meticulous management of concomitant medications are therefore paramount to achieving safe and effective drug exposure.

5.0 Clinical Evidence in Chronic Graft-Versus-Host Disease

The clinical efficacy and safety of Belumosudil for the treatment of cGVHD were definitively established in the pivotal ROCKstar trial. The results from this study provided the primary evidence supporting its regulatory approval and have defined its role in the management of this challenging disease.

5.1 The Pivotal ROCKstar (KD025-213) Trial: Design and Population (NCT03640481)

• Study Design: ROCKstar was a Phase 2, randomized, open-label, multicenter clinical trial designed to evaluate the efficacy and safety of Belumosudil in patients with cGVHD.[1] The study included two dose cohorts: 200 mg administered once daily (QD) and 200 mg administered twice daily (BID). The primary efficacy analysis for FDA approval was based on data from 65 patients in the 200 mg QD arm.[1] The full safety population for this dose comprised 83 patients who received at least one dose of Belumosudil 200 mg QD across two clinical studies (KD025-213 and KD025-208).[1]
• Patient Population: The trial enrolled a cohort of patients representative of a significant clinical challenge: individuals with advanced, treatment-refractory cGVHD. Eligible participants were adult and pediatric patients (aged 12 years and older) who had already received and failed between two and five prior lines of systemic therapy for their cGVHD.[9] This context is crucial for interpreting the trial's outcomes, as the study population had a poor prognosis and limited remaining therapeutic options.
• Baseline Characteristics: The enrolled patients were characterized by long-standing, severe, and multi-organ disease. The median time from cGVHD diagnosis to enrollment was over two years. A substantial majority of patients presented with severe cGVHD (67%), had four or more organs involved (52%), and were clinically refractory to their most recent line of therapy (72%).[9] This heavily pre-treated population provides a rigorous test for any new therapeutic agent.

5.2 Efficacy Analysis: Primary and Key Secondary Endpoints

Belumosudil demonstrated robust and clinically meaningful efficacy in this difficult-to-treat population.

• Primary Endpoint - Overall Response Rate (ORR): The primary efficacy endpoint, as defined for regulatory approval, was the ORR through Cycle 7 Day 1. In the 65-patient cohort receiving 200 mg QD, the ORR was 75% (95% Confidence Interval [CI], 63-85%).[8] This high response rate was composed of a 6% Complete Response (CR) rate and a 69% Partial Response (PR) rate, as defined by the 2014 National Institutes of Health (NIH) consensus criteria.[8] In the larger 132-patient dataset, the best ORR observed at any time during treatment was similarly high in both the QD arm (74%) and the BID arm (77%).[7]
• Durability of Response: While the formal CR rate was modest, the durability of the responses achieved was a standout feature of the trial. The median duration of response, as calculated by the FDA from the time of first response until disease progression, death, or initiation of new systemic therapy for cGVHD, was 1.9 months.[8] However, a more clinically impactful measure of durability was that among the patients who achieved a response, 62% (95% CI, 46-74%) remained alive and did not require any new systemic therapy for their cGVHD for at least 12 months from the onset of their response.[8] This finding indicates that for a majority of responders, Belumosudil provided a profound and long-lasting clinical benefit.
• Time to Response: The onset of clinical response was relatively rapid. The median time to the first documented response was 1.8 months [24], or approximately 5 weeks.[9]

The efficacy results of Belumosudil challenge a conventional, oncology-focused interpretation of treatment success. In the context of a chronic, debilitating, non-malignant condition like cGVHD, the therapeutic goals extend beyond complete eradication of all disease signs, which may be unachievable due to irreversible fibrotic damage. Instead, success is defined by halting disease progression, alleviating the symptomatic burden, improving quality of life, and reducing the toxicity of concomitant treatments, particularly corticosteroids. From this perspective, the high rate of durable partial responses, coupled with the profound steroid-sparing effect and symptomatic improvement, represents a major clinical achievement. The durability of the benefit, with a majority of responders remaining stable for over a year, is arguably a more important metric of success than the CR/PR ratio. This highlights that for chronic inflammatory diseases, endpoints that capture long-term disease control and quality of life, such as failure-free survival and reduction in treatment burden, are more reflective of true therapeutic value than traditional response criteria alone.

5.3 Impact on Organ-Specific Manifestations and Patient-Reported Outcomes

• Organ-Specific Responses: Belumosudil demonstrated efficacy across the wide spectrum of organs commonly affected by cGVHD. Clinically meaningful responses were observed in the skin, mouth, eyes, liver, lungs, joints/fascia, and the upper and lower gastrointestinal tract.[9]
• Tissue-Level Evidence: A companion study to ROCKstar provided direct, tissue-level confirmation of Belumosudil's proposed mechanism of action. In patients with oral cGVHD who responded to treatment, analysis of oral mucosal biopsies taken before and after therapy revealed a significant reduction in collagen content (confirming an anti-fibrotic effect) and a decrease in the frequency of IL-17-producing cells (confirming an anti-inflammatory effect).[7]
• Patient-Reported Outcomes: The objective clinical responses translated into tangible benefits for patients. A majority of participants (approximately 60%) reported a clinically meaningful improvement in their overall symptom burden, as measured by a decrease of at least 7 points on the Lee Symptom Scale (LSS) summary score.[9]

5.4 Corticosteroid-Sparing Effects and Survival

• Corticosteroid Reduction: A key secondary goal in cGVHD therapy is to reduce the dose of corticosteroids to minimize their significant long-term toxicities. Belumosudil treatment was highly effective in this regard. Approximately 65% of patients were able to reduce their daily corticosteroid dose, and a remarkable 21% of patients were able to discontinue corticosteroids completely.[9]
• Overall Survival: Despite the advanced and refractory nature of the disease in the study population, the 2-year overall survival rate was high, reported at 82% to 89%.[9] This survival outcome is particularly noteworthy in a population with a historically poor prognosis.

Endpoint	Result	Source(s)
Overall Response Rate (ORR) through Cycle 7 Day 1	75% (95% CI: 63-85%)	8
Complete Response (CR) Rate	6%	8
Partial Response (PR) Rate	69%	8
Median Time to First Response	1.8 months	24
Durability of Response (% of responders alive & without new systemic therapy at 12 months)	62% (95% CI: 46-74%)	8
2-Year Overall Survival Rate	82% (95% CI: 69-90%)	10
Corticosteroid Discontinuation Rate	~21%	9
Table 1: Key Efficacy Outcomes from the ROCKstar Trial (200 mg QD Cohort, n=65)

6.0 Safety and Tolerability Profile

The safety and tolerability of Belumosudil have been characterized through its clinical development program, primarily from the ROCKstar trial. The overall safety profile is considered manageable, particularly in the context of the heavily pre-treated cGVHD patient population, who often have numerous comorbidities and are receiving multiple immunosuppressive agents.

6.1 Common Adverse Reactions

The most frequently observed adverse reactions are generally mild to moderate in severity. In the safety population of 83 patients treated with Belumosudil 200 mg once daily, the most common adverse reactions (occurring in ≥20% of patients), including laboratory abnormalities, were: infections, asthenia (fatigue or weakness), nausea, diarrhea, dyspnea (shortness of breath), cough, edema (fluid retention or swelling), hemorrhage (bleeding), abdominal pain, musculoskeletal pain, headache, and hypertension (high blood pressure).[5] Laboratory abnormalities occurring at this frequency included decreased phosphate levels, increased gamma-glutamyl transferase (GGT), and decreased lymphocyte counts.[8] It is important to note that many of these events are also prevalent in the underlying cGVHD patient population, which can complicate direct attribution to the study drug.

Adverse Reaction (≥20% Incidence)	All Grades (%)	Grade 3-4 (%)
Infection, pathogen unspecified	53	16
Asthenia	46	4
Nausea	42	4
Diarrhea	35	5
Dyspnea	33	5
Cough	30	0
Edema	27	1
Hemorrhage	23	5
Musculoskeletal pain	22	4
Abdominal pain	22	1
Hypertension	21	7
Headache	21	0
Table 2: Incidence of Common Adverse Reactions in the Belumosudil 200 mg QD Safety Population (N=83) 11

6.2 Serious Adverse Reactions and Laboratory Abnormalities

• Infections: Infections were the most common adverse event overall and the most frequent Grade 3-4 event, occurring in 53% of patients (all grades) and 16% of patients (Grade 3-4).[11] However, a particularly noteworthy finding from the clinical studies was the remarkably low rate of cytomegalovirus (CMV) infection. In the clinical trial population, there were no new cases of CMV infection and only a single case of CMV reactivation.[10] This is a clinically significant safety signal, as patients with refractory cGVHD on multiple immunosuppressants are at an extremely high risk for opportunistic viral infections like CMV, which are a major cause of morbidity and mortality. This favorable profile suggests that Belumosudil's mechanism of action may differ qualitatively from that of traditional, broadly immunosuppressive agents. Rather than causing global T-cell suppression, its immunomodulatory action—which enhances Treg function while suppressing pathogenic Th17 cells—may preserve critical components of anti-viral immunity. This represents a significant potential advantage over other therapies.
• Hepatotoxicity: Belumosudil has been associated with elevations in serum aminotransferases.[13] In the safety cohort, elevations in ALT or AST of any grade occurred in 33% of patients. Elevations of Grade 3 or higher (defined as >5 times the upper limit of normal, ULN) occurred in 7% of patients.[13] These events were typically transient and manageable with dose interruption, but they necessitate diligent monitoring. The prescribing information mandates monitoring of total bilirubin, AST, and ALT at least monthly during treatment.[13] Specific guidelines are provided for dose modification or permanent discontinuation in the event of significant liver enzyme elevations.[11]
• Other Notable Events: Other Grade 3-4 adverse reactions of note included hypertension (7%), hemorrhage (5%), diarrhea (5%), and dyspnea (5%).[11]

6.3 Special Warnings and Precautions

The prescribing information for Belumosudil includes several important warnings and precautions that require careful patient selection and counseling.

• Embryo-Fetal Toxicity: Belumosudil can cause fetal harm when administered to a pregnant woman. This warning is based on its mechanism of action and findings from animal reproduction studies, which demonstrated embryo-fetal mortality and structural malformations at maternal exposures below those achieved in patients at the recommended clinical dose.[4] Consequently, the following risk mitigation strategies are mandatory:
• Pregnancy status must be verified in females of reproductive potential before initiating therapy.[22]
• Patients must be counseled on the potential risk to a fetus.
• Effective contraception is required for both female patients of reproductive potential and for male patients with female partners of reproductive potential. Contraception must be used throughout the duration of treatment and for at least one week after the final dose of Belumosudil.[12]
• Potential for Infertility: Based on findings in animal studies, Belumosudil may impair fertility in both males and females. These effects on fertility were observed to be reversible upon cessation of the drug in the animal models.[12] Patients of reproductive age should be counseled about this potential risk.[26]
• Lactation: There are no data on the presence of Belumosudil or its metabolites in human milk, the effects on a breastfed child, or the effects on milk production. Due to the potential for serious adverse reactions in a breastfed child, lactating women are advised not to breastfeed during treatment with Belumosudil and for at least one week after the last dose.[12]

7.0 Dosage, Administration, and Use in Specific Populations

This section provides practical, evidence-based guidance for the safe and effective clinical application of Belumosudil, including dosing, administration instructions, and considerations for specific patient populations.

7.1 Recommended Dosing and Administration

• Standard Dose: The recommended dosage of Belumosudil is 200 mg taken orally once daily.[12] This dose is applicable to both adult and pediatric patients 12 years of age and older.
• Administration Instructions: Adherence to specific administration instructions is critical for ensuring consistent drug exposure due to the drug's pharmacokinetic properties.
• Administration with Food: Belumosudil must be taken with a meal. This is a mandatory instruction based on pharmacokinetic data showing that food significantly increases the drug's absorption and overall exposure.[12]
• Timing: The dose should be taken at approximately the same time each day to maintain steady-state plasma concentrations.[12]
• Tablet Integrity: The tablets must be swallowed whole. They should not be cut, crushed, or chewed, as this could alter the release profile and absorption of the medication.[12]
• Missed Dose: If a patient misses a dose, they should be instructed to take it as soon as they remember on the same day. They should then resume their normal schedule the following day. Patients should be explicitly advised not to take extra doses to make up for a missed dose.[12]

7.2 Dose Modifications

The prescribing information provides specific guidelines for dose adjustments in the event of certain adverse reactions or drug interactions.

• For Adverse Reactions:
• Hepatotoxicity: For Grade 3 AST or ALT elevation (>5 to 20 × ULN) or Grade 2 bilirubin elevation (>1.5 to 3 × ULN), Belumosudil should be withheld until the abnormalities recover to Grade 1 or less. Treatment can then be resumed at the standard 200 mg once daily dose. For more severe hepatotoxicity (Grade 4 AST or ALT, or Grade ≥3 bilirubin), Belumosudil must be permanently discontinued.[11]
• Other Adverse Reactions: For other Grade 3 adverse reactions, treatment should be held until the event resolves to Grade 1 or baseline, after which it can be resumed at the standard dose. For any Grade 4 adverse reaction, Belumosudil should be permanently discontinued.[11]
• For Drug Interactions:
• Strong CYP3A Inducers: When Belumosudil is co-administered with a strong inducer of the CYP3A enzyme, its dosage must be increased to 200 mg twice daily.[14]
• Proton Pump Inhibitors (PPIs): When Belumosudil is co-administered with a proton pump inhibitor, its dosage must also be increased to 200 mg twice daily.[14] This counterintuitive dose escalation reveals a significant pharmacokinetic liability. PPIs work by profoundly increasing gastric pH. The need to double the Belumosudil dose in their presence strongly suggests that Belumosudil's solubility and subsequent absorption are pH-dependent and are significantly reduced in a less acidic environment. This is a critical management point, as PPIs are ubiquitous in the post-transplant population. Failure to identify concomitant PPI use and appropriately increase the Belumosudil dose could lead to sub-therapeutic drug exposure and treatment failure.

7.3 Use in Specific Populations

• Pediatric Population: Belumosudil is approved for use in pediatric patients aged 12 years and older.[12] The safety and efficacy in children younger than 12 years have not been established.[12] A Phase 1/2 clinical trial (schoolROCK, NCT07116031) is currently underway to evaluate the pharmacokinetics, safety, and efficacy of Belumosudil in children aged 1 to <18 years to establish a recommended pediatric dose for younger age groups.[29]
• Geriatric Population: No dose adjustment is recommended for patients aged 65 years and older. Clinical trials included a substantial proportion of geriatric patients (25.8%), and the data did not reveal any specific safety or efficacy concerns that would limit its usefulness in this population.[12]
• Hepatic Impairment: The liver is the primary site of Belumosudil's elimination. No dose adjustment is required for patients with mild hepatic impairment (Child-Pugh Class A). However, due to expected increases in drug exposure, the use of Belumosudil should be avoided in patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment, unless the impairment is due to liver GVHD.[14]
• Renal Impairment: Pharmacokinetic studies have shown that mild to moderate renal impairment does not have a clinically significant effect on Belumosudil exposure. The drug has not been studied in patients with pre-existing severe renal impairment, so it should be used with caution in this population.[11]

8.0 Clinically Significant Drug Interactions

The safe use of Belumosudil is highly dependent on the careful management of drug-drug interactions. Its pharmacokinetic profile makes it both susceptible to the effects of other drugs and capable of altering the concentrations of concomitant medications. This bidirectional interaction profile is particularly important in the cGVHD population, where polypharmacy is standard and many patients are on narrow-therapeutic-index immunosuppressants.

8.1 Effects of Other Drugs on Belumosudil

The plasma concentration and potential efficacy of Belumosudil can be significantly reduced by two main classes of drugs.

• Strong CYP3A4 Inducers:
• Mechanism: Belumosudil is primarily metabolized by the CYP3A4 enzyme. Strong inducers of this enzyme, such as the antibiotic rifampin, the anticonvulsants carbamazepine and phenytoin, and the herbal supplement St. John's wort, can dramatically increase the rate of Belumosudil's metabolism.[15]
• Clinical Effect: This accelerated clearance leads to a significant decrease in the plasma concentration and total exposure (AUC) of Belumosudil, which may compromise its therapeutic efficacy.[4]
• Management: To counteract this effect, it is necessary to increase the Belumosudil dosage to 200 mg twice daily when co-administered with a strong CYP3A4 inducer.[14]
• Proton Pump Inhibitors (PPIs):
• Mechanism: As previously discussed, PPIs such as omeprazole, lansoprazole, and esomeprazole increase gastric pH. This change in acidity appears to reduce the solubility and subsequent absorption of Belumosudil from the gastrointestinal tract.[28]
• Clinical Effect: The reduced absorption leads to lower plasma concentrations of Belumosudil, which may reduce its efficacy.[15]
• Management: To compensate for the reduced absorption, the dosage of Belumosudil must be increased to 200 mg twice daily when given concurrently with a PPI.[14]

8.2 Effects of Belumosudil on Other Drugs

Belumosudil can also act as the perpetrator in drug interactions, most notably by increasing the concentrations of other commonly used immunosuppressants.

• Immunosuppressants (Tacrolimus and Sirolimus):
• Mechanism: Tacrolimus and sirolimus are both substrates of CYP3A4 and the drug efflux transporter P-glycoprotein (P-gp). In vitro data suggest that Belumosudil is a weak inhibitor of CYP3A and an inhibitor of P-gp.[31] By inhibiting these pathways, Belumosudil can reduce the clearance of tacrolimus and sirolimus.
• Clinical Effect: This interaction is not merely theoretical; it is clinically significant and has been demonstrated in a retrospective clinical study. The addition of Belumosudil to a patient's regimen led to a statistically significant increase in the concentration-to-dose (C/D) ratio of both sirolimus (a 160% increase) and tacrolimus (a 113% increase).[31] This can easily push the levels of these narrow-therapeutic-index drugs into the supratherapeutic and potentially toxic range, increasing the risk of adverse effects such as nephrotoxicity. The study also noted that the C/D ratio continued to increase over time after Belumosudil initiation, indicating a complex interaction that requires sustained monitoring.[31]
• Management: Proactive management is essential. When initiating Belumosudil in a patient taking tacrolimus or sirolimus, close therapeutic drug monitoring is required. The evidence supports making an empiric dose reduction of the concomitant immunosuppressant at the time of Belumosudil initiation. Recommendations from the study suggest a dose reduction of 25% for tacrolimus and 25-50% for sirolimus, followed by frequent monitoring of drug levels and further dose adjustments as needed to maintain therapeutic concentrations.[31]

The complex, bidirectional nature of Belumosudil's drug interaction profile positions it as a medication that requires expert-level pharmacotherapeutic oversight. Its introduction into a patient's regimen is not a simple addition but necessitates a comprehensive recalibration of their entire immunosuppressive plan. The clinician must be vigilant not only about drugs that might reduce Belumosudil's efficacy but also about Belumosudil's potent ability to increase the toxicity of other critical medications. This underscores the essential role of the clinical pharmacist in the care team to ensure the safe and effective use of this novel agent.

Concomitant Drug Class	Example Drugs	Effect on Belumosudil or Concomitant Drug	Recommended Clinical Management
Strong CYP3A Inducers	Rifampin, Phenytoin, Carbamazepine, St. John's wort	Decreased plasma exposure of Belumosudil, potentially reducing efficacy.	Increase Belumosudil dosage to 200 mg twice daily. 14
Proton Pump Inhibitors (PPIs)	Omeprazole, Lansoprazole, Esomeprazole	Decreased absorption and exposure of Belumosudil, potentially reducing efficacy.	Increase Belumosudil dosage to 200 mg twice daily. 14
Calcineurin / mTOR Inhibitors	Tacrolimus, Sirolimus	Increased plasma exposure of tacrolimus and sirolimus, risking toxicity.	Empirically reduce tacrolimus/sirolimus dose by 25-50% upon initiation. Monitor drug levels closely and frequently, and adjust doses as needed. 31
Table 3: Guide to Managing Key Drug-Drug Interactions with Belumosudil

9.0 Regulatory and Developmental History

The journey of Belumosudil from a novel chemical entity to an approved therapy was marked by a focused development program and expedited regulatory pathways, reflecting the significant unmet need in chronic graft-versus-host disease.

• Discovery and Early Development: Belumosudil (then known as SLx-2119) was originally discovered and developed by Surface Logix, Inc. The compound and its associated program were later acquired by Kadmon Corporation, LLC (which has since been acquired by Sanofi), who advanced it through pivotal clinical trials.[1]
• Regulatory Designations: Recognizing its potential to address a serious and life-threatening condition with limited treatment options, the U.S. FDA granted Belumosudil several key designations to facilitate its development. In October 2017, it received Orphan Drug designation for the treatment of cGVHD.[1] It was also granted Breakthrough Therapy designation, a status reserved for drugs that may demonstrate substantial improvement over available therapy on a clinically significant endpoint, which allows for more intensive FDA guidance and a potentially expedited review.[34]
• FDA Approval Timeline: The final stages of its development and review process proceeded rapidly:
• May 21, 2020: Kadmon announced positive topline results from the pivotal ROCKstar trial, which met its primary endpoint.[25]
• September 30, 2020: The company submitted a New Drug Application (NDA) to the U.S. FDA.[25]
• November 30, 2020: The FDA formally accepted the NDA for review, setting a target action date.[25]
• July 16, 2021: The FDA granted full approval to Belumosudil (Rezurock®) for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy.[1] The review process was notably efficient, utilizing the FDA's Real-Time Oncology Review (RTOR) pilot program, which allows for the review of data before the complete application is formally submitted. This, along with the Assessment Aid tool, facilitated an approval that was granted six weeks ahead of the scheduled Prescription Drug User Fee Act (PDUFA) goal date.[24]
• Global Regulatory Status: Following its approval in the United States, Belumosudil has gained recognition from other international regulatory bodies. In December 2023, the National Institute for Health and Care Excellence (NICE) in the United Kingdom issued a positive final draft guidance, recommending Belumosudil for use within the National Health Service (NHS) for patients in England and Wales, making it the first therapy for this specific indication to be funded in this region.[35]

10.0 Future Horizons: Investigational Uses and Ongoing Research

The approval of Belumosudil in cGVHD has served as a powerful clinical proof-of-concept for the therapeutic potential of selective ROCK2 inhibition. The drug's unique dual mechanism, which targets the fundamental processes of dysregulated inflammation and fibrosis, provides a strong scientific rationale for its investigation in a wide range of other diseases that share this underlying pathology. Consequently, Belumosudil is being actively explored in numerous clinical trials beyond its current indication, positioning it as a potential platform therapy for various fibro-inflammatory conditions.

10.1 Rationale for Broader Applications

The common pathological thread linking conditions such as idiopathic pulmonary fibrosis, psoriasis, and transplant-related complications like bronchiolitis obliterans is a self-perpetuating cycle of immune activation (often involving Th17 pathways) and progressive tissue fibrosis.[6] Because Belumosudil's mechanism is not specific to the alloimmune context of cGVHD but rather targets the core cellular machinery of these processes, it holds promise as a treatment across multiple medical specialties. The extensive and diverse ongoing clinical trial program reflects a strategic effort to leverage this core mechanism and expand its utility far beyond the initial approval.

10.2 Investigational Uses

• Idiopathic Pulmonary Fibrosis (IPF): IPF is a devastating and progressive lung disease characterized by extensive fibrosis. Increased ROCK activity has been identified in the lungs of patients with IPF. Preclinical studies have shown that treatment with Belumosudil significantly reduced lung fibrosis in a bleomycin-induced mouse model of the disease, providing a strong rationale for its clinical investigation in this setting.[1]
• Psoriasis: Psoriasis is a chronic inflammatory skin condition. Phase 2 clinical studies (NCT02317627, NCT02106195) in patients with moderate to severe psoriasis vulgaris demonstrated that treatment with Belumosudil led to a down-regulation of pro-inflammatory responses, suggesting it may be a viable therapeutic option.[1]
• Other Potential Uses: Belumosudil has also been investigated for the treatment of pulmonary arterial hypertension.[18]

10.3 Current Clinical Trials Landscape

The current clinical trial portfolio for Belumosudil is broad, exploring its use in different stages of cGVHD as well as in other transplant-related complications and solid organ transplantation.

• Within cGVHD:
• Pre-emptive Therapy: A Phase 2 trial (NCT05996627) is evaluating whether initiating Belumosudil in patients with early signs of cGVHD can prevent the progression to more severe disease requiring full systemic immunosuppression.[37]
• First-Line Therapy: A Phase 2 study (NCT06046248) is investigating Belumosudil in combination with rituximab as a primary, first-line treatment for newly diagnosed cGVHD, aiming to move its use earlier in the treatment paradigm.[40]
• Prevention: Another trial is exploring the use of Belumosudil as a prophylactic agent to prevent the initial development of cGVHD after transplantation.[37]
• Other Transplant Complications:
• Bronchiolitis Obliterans Syndrome (BOS): BOS is a form of chronic lung allograft rejection characterized by inflammation and fibrosis of the small airways. The BEBOP trial (NCT05922761), a Phase 2 study, is assessing the efficacy of Belumosudil in treating patients with new-onset or incipient BOS following hematopoietic cell transplant.[37]
• Chronic Lung Allograft Dysfunction (CLAD): A randomized, placebo-controlled trial (NCT06476132) is underway to determine if Belumosudil can prevent the development of CLAD in high-risk lung transplant recipients.[42]
• Solid Organ Transplantation:
• Kidney Transplant Tolerance: A Phase 1 trial (NCT05806749) is studying whether Belumosudil can help promote immunological tolerance in patients receiving mismatched kidney transplants, potentially reducing the need for long-term, broad immunosuppression.[43]

This expansive research program underscores the belief that Belumosudil is more than a single-indication drug. Its success has validated selective ROCK2 inhibition as a therapeutic strategy, potentially unlocking a "pipeline in a pill" with the capacity to treat a host of challenging diseases across immunology, pulmonology, dermatology, and transplant medicine.

11.0 Concluding Analysis and Clinical Recommendations

Belumosudil (Rezurock®) represents a landmark therapeutic advance in the management of chronic graft-versus-host disease. It is a transformative agent that offers a novel, targeted approach for a patient population with a historically poor prognosis and limited treatment options.

11.1 Synthesis of Belumosudil's Value Proposition

The core value of Belumosudil lies in its unique mechanism of action, which precisely targets the dual pathology of inflammation and fibrosis that drives cGVHD. This is a departure from the broad, non-specific immunosuppression that has long been the cornerstone of therapy. Clinical evidence from the ROCKstar trial has robustly demonstrated that this mechanism translates into high and, critically, durable clinical responses in a profoundly treatment-refractory population. The ability to achieve long-term disease control, coupled with a significant corticosteroid-sparing benefit and improvements in patient-reported quality of life, establishes Belumosudil as a vital new standard of care for patients with cGVHD who have failed at least two prior lines of therapy.

11.2 Advantages and Limitations

• Key Advantages:
• Novel Dual Mechanism: Simultaneously targets inflammation and fibrosis.
• High Efficacy: Demonstrates high ORR in a heavily pre-treated, refractory population.
• Durable Responses: Provides long-lasting disease control for a majority of responders.
• Steroid-Sparing: Allows for significant reduction or discontinuation of corticosteroids.
• Favorable Infection Profile: Appears to have a low risk of inducing opportunistic viral infections like CMV.
• Oral Administration: Offers the convenience of an at-home, oral regimen.
• Key Limitations:
• Lack of Comparator: The pivotal trial was single-arm for the approved dose, lacking a direct, active comparator.
• Complex Drug Interactions: Possesses a significant and bidirectional drug interaction profile that requires expert pharmacotherapeutic management.
• Key Safety Warnings: Carries important warnings for embryo-fetal toxicity, potential infertility, and hepatotoxicity that require careful monitoring and patient counseling.

11.3 Expert Recommendations for Optimal Clinical Use

The successful integration of Belumosudil into clinical practice requires a meticulous and proactive approach to management. While its efficacy is clear, its safe and effective use is intrinsically linked to the careful handling of its pharmacokinetic and pharmacodynamic complexities.

1. Patient Selection: Belumosudil should be utilized in accordance with its approved indication for patients with cGVHD who have failed at least two prior lines of systemic therapy. It is an especially strong candidate for patients with multi-organ disease, those with prominent fibrotic manifestations (e.g., scleroderma, bronchiolitis obliterans), and in cases where corticosteroid toxicity is a primary clinical concern.
2. Pre-treatment Workup: Before initiating therapy, a comprehensive medication review is mandatory to identify and plan for the management of interacting drugs, particularly strong CYP3A inducers, proton pump inhibitors, tacrolimus, and sirolimus. A negative pregnancy test must be confirmed for all females of reproductive potential. Baseline liver function tests (bilirubin, AST, ALT) should be obtained.
3. Patient Counseling: Thorough patient education is paramount. Patients must understand the critical importance of taking the medication with a meal at the same time each day. They must be counseled extensively on the mandatory use of effective contraception (for both sexes), the potential risk to fertility, and the need to avoid breastfeeding. Patients should also be educated on the signs and symptoms of liver toxicity and instructed to report them immediately.
4. Proactive Management of Drug Interactions: Clinicians must not wait for adverse events to occur. They should anticipate and proactively manage drug interactions from the outset. This includes doubling the Belumosudil dose to 200 mg BID for patients on strong CYP3A inducers or PPIs. For patients on tacrolimus or sirolimus, an empiric dose reduction of 25-50% should be made upon starting Belumosudil, with a clear plan for frequent therapeutic drug monitoring to guide further adjustments.
5. Ongoing Monitoring: Liver function tests must be monitored at least monthly throughout the course of treatment. Patients should be assessed regularly for clinical response, the emergence of adverse events, and continued adherence to the administration and safety requirements.

11.4 Final Perspective

Belumosudil is a transformative addition to the therapeutic armamentarium for chronic graft-versus-host disease. Its success has not only provided a much-needed option for patients but has also validated selective ROCK2 inhibition as a powerful and promising therapeutic strategy. This validation is paving the way for the investigation of Belumosudil and other ROCK2 inhibitors in a much broader spectrum of debilitating fibro-inflammatory disorders, offering hope for many other patient populations in the future.

Works cited

1. Belumosudil - Wikipedia, accessed August 21, 2025, https://en.wikipedia.org/wiki/Belumosudil
2. www.rezurock.com, accessed August 21, 2025, https://www.rezurock.com/#:~:text=REZUROCK%C2%AE%20(belumosudil)%20is%20a,and%20they%20did%20not%20work.
3. pubmed.ncbi.nlm.nih.gov, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/40318736/#:~:text=Belumosudil%20is%20an%20oral%20selective,prior%20systemic%20lines%20of%20therapy.
4. REZUROCK® (belumosudil) | Official HCP Website, accessed August 21, 2025, https://www.rezurockhcp.com/
5. REZUROCK® (belumosudil) Mechanism of Action, accessed August 21, 2025, https://www.rezurockhcp.com/rezurock-mechanism-of-action
6. What is the mechanism of Belumosudil? - Patsnap Synapse, accessed August 21, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-belumosudil
7. Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study | Blood Advances | American Society of Hematology, accessed August 21, 2025, https://ashpublications.org/bloodadvances/article/9/14/3479/537087/Belumosudil-reduces-oral-chronic-graft-versus-host
8. FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/35135839/
9. Formulary Drug Review: Belumosudil - PMC, accessed August 21, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310299/
10. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of ..., accessed August 21, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.20.02754
11. Formulary Drug Review: Belumosudil - PMC, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9310299/
12. Belumosudil (oral route) - Side effects & dosage - Mayo Clinic, accessed August 21, 2025, https://www.mayoclinic.org/drugs-supplements/belumosudil-oral-route/description/drg-20518757
13. Belumosudil - LiverTox - NCBI Bookshelf, accessed August 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK605691/
14. Belumosudil Tablets 200mg REZUROCK® - Sanofi, accessed August 21, 2025, https://www.sanofi.com/assets/countries/india/docs/science-and-innovation/for-healthcare-professionals/product-information/pharmaceuticals/Rezurock--PI.pdf
15. Belumosudil: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 21, 2025, https://www.rxlist.com/belumosudil/generic-drug.htm
16. Belumosudil | 911417-87-3 - ChemicalBook, accessed August 21, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82624291.htm
17. KD 025 (Belumosudil, SLx-2119, CAS Number: 911417-87-3) | Cayman Chemical, accessed August 21, 2025, https://www.caymanchem.com/product/17055/kd-025
18. 2-(3-(4-(1H-Indazol-5-ylamino)-2-quinazolinyl)phenoxy)-N-(1-methylethyl)acetamide - PubChem, accessed August 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Belumosudil
19. Predicted MS/MS Spectrum - 10V, Positive (Annotated) (DB16703, accessed August 21, 2025, https://go.drugbank.com/spectra/ms_ms/593834
20. Abridged Prescribing Information Belumosudil Tablets 200mg REZUROCK® Composition - Sanofi, accessed August 21, 2025, https://www.sanofi.com/assets/countries/india/docs/science-and-innovation/for-healthcare-professionals/product-information/pharmaceuticals/Rezurock--API.pdf
21. Belumosudil for chronic graft-versus-host disease - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/35535812/
22. This label may not be the latest approved by FDA. For current ..., accessed August 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214783s000lbl.pdf
23. Belumosudil Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 21, 2025, https://www.drugs.com/dosage/belumosudil.html
24. FDA D.I.S.C.O. Burst Edition: FDA approval of Rezurok (belumosudil) for adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy, accessed August 21, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-rezurok-belumosudil-adult-and-pediatric-patients-12-years-and
25. Rezurock (belumosudil) FDA Approval History - Drugs.com, accessed August 21, 2025, https://www.drugs.com/history/rezurock.html
26. Clinical Studies & Side Effects | REZUROCK® (belumosudil) 200-mg Tablet, accessed August 21, 2025, https://www.rezurock.com/chronic-gvhd
27. Belumosudil Monograph for Professionals - Drugs.com, accessed August 21, 2025, https://www.drugs.com/monograph/belumosudil.html
28. Belumosudil Uses, Side Effects & Warnings - Drugs.com, accessed August 21, 2025, https://www.drugs.com/mtm/belumosudil.html
29. A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) | ClinicalTrials.gov, accessed August 21, 2025, https://clinicaltrials.gov/study/NCT07116031
30. Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12227017/
31. Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/37355201/
32. Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-Versus-Host Disease | Blood | American Society of Hematology, accessed August 21, 2025, https://ashpublications.org/blood/article/140/Supplement%201/10512/487142/Belumosudil-Impacts-Immunosuppression
33. Impact of belumosudil on tacrolimus & sirolimus pharmacokinetics in patients with chronic GvHD - YouTube, accessed August 21, 2025, https://www.youtube.com/watch?v=x1Q9o_0X1tE
34. REZUROCK (belumosudil) tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson, accessed August 21, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2021/rezurock-fda-approved-treatment-chronic-graft-versus-host-disease/
35. NICE Shares Positive Opinion on Belumosudil for Chronic GVHD - CancerNetwork, accessed August 21, 2025, https://www.cancernetwork.com/view/nice-shares-positive-opinion-on-belumosudil-for-chronic-gvhd
36. Belumosudil Completed Phase 2 Trials for Psoriasis Vulgaris (Plaque Psoriasis) Treatment | DrugBank Online, accessed August 21, 2025, https://go.drugbank.com/drugs/DB16703/clinical_trials?conditions=DBCOND0070073&phase=2&purpose=treatment&status=completed
37. Clinical Trials Using Belumosudil - NCI, accessed August 21, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/belumosudil?pn=1
38. Belumosudil for the Pre-emptive Treatment of Patients with Chronic Graft Versus Host Disease - National Cancer Institute, accessed August 21, 2025, https://www.cancer.gov/clinicaltrials/NCI-2023-05293
39. Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease | ClinicalTrials.gov, accessed August 21, 2025, https://www.clinicaltrials.gov/study/NCT05996627?cond=Chronic%20graft%20versus%20host%20disease%20OR%20%22graft%20versus%20host%20disease,%20chronic%22%20OR%20%22%20GVHD,%20chronic%22&aggFilters=status:not%20rec&viewType=Table&rank=9
40. Study Details | Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease | ClinicalTrials.gov, accessed August 21, 2025, https://clinicaltrials.gov/study/NCT06046248
41. Study Details | BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) | ClinicalTrials.gov, accessed August 21, 2025, https://www.clinicaltrials.gov/study/NCT05922761
42. Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients (CLAD) - ClinicalTrials.gov, accessed August 21, 2025, https://clinicaltrials.gov/study/NCT06476132
43. Belumosudil Active Not Recruiting Phase 1 Trials for Immunological Tolerance / End Stage Kidney Disease (ESRD) / Chronic Kidney Disease (CKD) / Kidney Transplant Failure and Rejection Treatment - DrugBank, accessed August 21, 2025, https://go.drugbank.com/drugs/DB16703/clinical_trials?conditions=DBCOND0048800%2CDBCOND0148133%2CDBCOND0151232%2CDBCOND0032007&phase=1&purpose=treatment&status=active_not_recruiting